Here is one of the stranger realities of the private capital markets: a company can become objectively better and simultaneously become harder to finance.
That sounds backwards, right?
Investors are supposed to reward progress. You complete the clinical trial, get FDA clearance, launch the product, sign customers, grow revenue, land the strategic partnership. Risk comes out of the business, so presumably the valuation goes up and the next round gets easier.
Not always.